Spain Cancer Pain Management Market Forecast 2024-2032

List of Tables

KEY FINDINGS

The Spain cancer pain management market is projected to grow with a CAGR of 5.32% during the forecast period 2024-2032.

MARKET INSIGHTS

REDECAN's 2024 cancer incidence estimates for Spain project a total of 286,664 new cases, with 161,678 in males and 124,986 in females. Among men, the most prevalent cancers are prostate (30,316 cases), lung (22,483 cases), urinary bladder (18,247 cases), colon (17,793 cases), and rectum (9,216 cases). For women, breast cancer leads with 36,395 cases, followed by colon (11,855 cases), lung (10,285 cases), uterine body (7,305 cases), and rectum (5,430 cases).

Cancer incidence in Spain varies significantly by age group. 15,938 new cases are expected in individuals aged 0 to 44 (5.6% of total cancers), 99,391 cases in those aged 45 to 64 (34.7% of total cancers), and 171,335 cases in those aged 65 and older (59.8% of total cancers). This growing cancer prevalence highlights the urgent need for advanced pain management strategies. Healthcare providers are increasingly focusing on improving cancer patient's quality of life through comprehensive pain management solutions.

As of January 2023, Spain's elderly population aged over 65 numbered 9.68 million, continuing a growth trend since 2002, when this population increased by over two million. Currently, people over 65 constitute nearly one-fifth of Spain's total population. The significant rise in cancer cases, particularly among the elderly, emphasizes the critical need for effective pain management solutions. The increasing number of elderly individuals who are more susceptible to cancer drives the demand for specialized cancer pain management services tailored to their specific needs.

Personalized medicine, which tailors treatment to individual patient characteristics such as genetic profile, can enhance the effectiveness and reduce the side effects of cancer pain therapies. This approach is particularly relevant as Spain experiences a rise in cancer cases, necessitating more targeted and efficient cancer pain treatment strategies. Personalized therapies provide tailored pain relief, improving the quality of life for cancer patients and addressing diverse pain management needs more precisely than traditional one-size-fits-all treatments.

SEGMENTATION ANALYSIS

The report on the Spain cancer pain management market includes the segmentation analysis based on drug type and disease indication.

Market by Drug Type:

Opioids
Morphine
Fentanyl
Other Morphines
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory drugs (NSAIDS)
Nerve Blockers

Market by Disease Indication:

Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Blood Cancer
Other Disease Indications

Inkwood Research's report on the Spain cancer pain management market provides in-depth insights as well as the market's segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis.

COMPETITIVE ANALYSIS

Key players operating in the Spain cancer pain management market include Daiichi Sankyo Company Ltd, Shionogi & Co Ltd, Pfizer, Teva Pharmaceutical Industries Limited, Mundipharma International, Grunenthal Pharma GmbH & Co KG.

Daiichi Sankyo Co Ltd, headquartered in Tokyo, Japan, is a holding company that manufactures and sells pharmaceuticals. The company focuses on various therapeutic areas, including infectious diseases, cardiovascular diseases, bone and joint diseases, and contrast media. Operating across Asia, Europe, and the Americas, Daiichi Sankyo offers its products and services in over 20 countries worldwide.

Product Code: 90643

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT - SPAIN
2.3. COUNTRY ANALYSIS - SPAIN
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
- 2.5.1. IMPACT OF COVID-19 ON THE SPAIN CANCER PAIN MANAGEMENT MARKET
2.6. MAJOR MARKET FINDINGS
- 2.6.1. INNOVATIONS IN PALLIATIVE CARE
- 2.6.2. SURGE IN PERSONALIZED MEDICINE APPROACHES
- 2.6.3. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INCREASING PREVALENCE OF CANCER IN SPAIN
- 3.1.2. SURGE IN GERIATRIC POPULATION
- 3.1.3. ADVANCED HEALTHCARE INFRASTRUCTURE
3.2. KEY RESTRAINTS
- 3.2.1. REGULATORY CHALLENGES AND APPROVAL DELAYS
- 3.2.2. HIGH COST OF TREATMENT
- 3.2.3. OPIOID SIDE EFFECTS AND ADDICTION CONCERNS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. ADVANCEMENTS IN MEDICAL TECHNOLOGY IN SPAIN
- 4.1.2. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
- 4.1.3. ACTIVE R&D BY PHARMACEUTICAL COMPANIES
4.2. PESTLE ANALYSIS
- 4.2.1. POLITICAL
- 4.2.2. ECONOMICAL
- 4.2.3. SOCIAL
- 4.2.4. TECHNOLOGICAL
- 4.2.5. LEGAL
- 4.2.6. ENVIRONMENTAL
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTIONS
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING - SPAIN
4.5. VALUE CHAIN ANALYSIS
- 4.5.1. RESEARCH & DEVELOPMENT
- 4.5.2. REGULATORY APPROVAL
- 4.5.3. MANUFACTURING
- 4.5.4. DISTRIBUTION
- 4.5.5. END-USERS

5. MARKET BY DRUG TYPE

5.1. OPIOIDS
5.2. MORPHINE
- 5.2.1. FENTANYL
- 5.2.2. OTHER MORPHINES
5.3. NON-OPIOIDS
5.4. ACETAMINOPHEN
5.5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.6. NERVE BLOCKERS

6. MARKET BY DISEASE INDICATION

6.1. LUNG CANCER
6.2. COLORECTAL CANCER
6.3. BREAST CANCER
6.4. PROSTATE CANCER
6.5. BLOOD CANCER
6.6. OTHER DISEASE INDICATIONS

7. COMPETITIVE LANDSCAPE

7.1. KEY STRATEGIC DEVELOPMENTS
- 7.1.1. MERGERS & ACQUISITIONS
- 7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 7.1.3. PARTNERSHIPS & AGREEMENTS
- 7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
- 7.2.1. DAIICHI SANKYO COMPANY LIMITED
  - 7.2.1.1. COMPANY OVERVIEW
  - 7.2.1.2. PRODUCTS
  - 7.2.1.3. STRENGTHS & CHALLENGES
- 7.2.2. SHIONOGI & CO LTD
  - 7.2.2.1. COMPANY OVERVIEW
  - 7.2.2.2. PRODUCTS
  - 7.2.2.3. STRENGTHS & CHALLENGES
- 7.2.3. PFIZER
  - 7.2.3.1. COMPANY OVERVIEW
  - 7.2.3.2. PRODUCTS
  - 7.2.3.3. STRENGTHS & CHALLENGES
- 7.2.4. TEVA PHARMACEUTICAL INDUSTRIES
  - 7.2.4.1. COMPANY OVERVIEW
  - 7.2.4.2. PRODUCTS
  - 7.2.4.3. STRENGTHS & CHALLENGES
- 7.2.5. MUNDIPHARMA INTERNATIONAL
  - 7.2.5.1. COMPANY OVERVIEW
  - 7.2.5.2. PRODUCTS
  - 7.2.5.3. STRENGTHS & CHALLENGES
- 7.2.6. GRUNENTHAL PHARMA GMBH & CO KG
  - 7.2.6.1. COMPANY OVERVIEW
  - 7.2.6.2. PRODUCTS
  - 7.2.6.3. STRENGTHS & CHALLENGES